ReviewBMC cancer2011
Increased fracture rate in women with breast cancer: a review of the hidden risk.
Review in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.Journal of Korean medical science · 2020Pooled it
- Weight lifting and appendicular skeletal muscle mass among breast cancer survivors: a randomized controlled trial.Breast cancer research and treatment · 2015Trial
- Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a nationwide cohort study.Scientific reports · 2025Article
- Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer.BMC cancer · 2022Article
- The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- The association between comorbidities and stigma among breast cancer survivors.Scientific reports · 2022Article
- Article
- Osteoporosis, fracture and survival: Application of machine learning in breast cancer prediction models.Frontiers in oncology · 2022Article
- Risk of osteoporosis and fracture in long-term breast cancer survivors.Korean journal of clinical oncology · 2020Article
- Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study.Frontiers in oncology · 2020Article
- Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship.The Permanente journal · 2020Article
- BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life" Experience (BOHEME Study).Journal of clinical medicine · 2019Article
- Soy Food Consumption, Exercise, and Body Mass Index and Osteoporotic Fracture Risk Among Breast Cancer Survivors: The Shanghai Breast Cancer Survival Study.JNCI cancer spectrum · 2019Article
- Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- External Beam Irradiation Preferentially Inhibits the Endochondral Pathway of Fracture Healing: A Rat Model.Clinical orthopaedics and related research · 2018Article
- Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis.Therapeutic advances in musculoskeletal disease · 2018Review
- Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.BMC cancer · 2018Article
- Identifying predictive motor factors for falls in post-menopausal breast cancer survivors.PloS one · 2017Article
- Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem.Journal of breast cancer · 2015Review
- Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.The Permanente journal · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWomen with breast cancer, particularly individuals diagnosed at a relatively early age, have an increased incidence of fractures. Fractures can have serious clinical consequences including the need for major surgery, increased morbidity and mortality, increased cost of disease management, and reduced quality of life for patients. The primary cause of the increased fracture risk appears to be an accelerated decrease in bone mineral density (BMD) resulting from the loss of estrogenic signaling that occurs with most treatments for breast cancer, including aromatase inhibitors. However, factors other than BMD levels alone may influence treatment decisions to reduce fracture risk in this setting. Our purpose is to review current evidence for BMD loss and fracture risk during treatment for breast cancer and discuss pharmacologic means to reduce this risk.
resultsFracture risk during treatment for breast cancer may be influenced by the rate of BMD loss and the consequent rapid alterations in bone microarchitecture, in addition to the established fracture risk factors in postmenopausal osteoporosis. The rapid decrease in BMD during adjuvant chemoendocrine therapy for breast cancer may necessitate more aggressive pharmacotherapy than is indicated for healthy postmenopausal women who develop osteoporosis. Over the last few years, clinical trials have established the effectiveness of bisphosphonates and other antiresorptive agents to preserve BMD during adjuvant therapy for early breast cancer. In addition, some bisphosphonates (eg, zoledronic acid) may also delay disease recurrence in women with hormone-responsive tumors, thereby providing an adjuvant benefit in addition to preserving BMD and potentially preventing fractures.
conclusionsIt is likely that a combined fracture risk assessment (eg, as in the WHO FRAX algorithm) will more accurately identify both women with postmenopausal osteoporosis and women with breast cancer who require bone-protective therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.